Page 14 - I Mab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from I mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In I Mab Today - Breaking & Trending Today

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization. ....

United States , Hong Kong , Emilie Wu , Deepa Gotur , Joan Shen , Gigi Feng , Jielun Zhu , Exchange Commission , Prnewswire The Company Nasdaq , Piacente Group Inc , Lymphocyte Ratio , Private Securities Litigation Reform Act , Chief Financial , Chief Communications , Piacente Group , I Mab , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , எமிலீ வு , தீபா கோட்டூர் , ஜோன் ஷென் , பல் ஃபெங் , பரிமாற்றம் தரகு , பியசெந்தே குழு இன்க் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , தலைமை நிதி ,

I-Mab Appoints Ruyi He and Rong Shao to Board of Directors

Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., June 1, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the Company s board of directors. Dr. Ruyi He will serve on the compensation committee and Professor Shao will serve on the corporate governance committee both effective June 1, 2021.
We are honored to welcome Dr. He and Professor Shao to our board, and look forward to their wealth of industry experience and breadth of relationships as we transform into a fully integrated global biopharmaceutical company. Both Dr. He and Professor Shao are leading experts in their respective fields, and their appointments will further strengthen I-Mab s next phase of growth, said Dr. Jingwu Zang, Founder, Chairman and Director of I-Mab. ....

National Institutes Of Health , United States , Hong Kong , San Diego , Howard University Hospital , District Of Columbia , Emilie Wu , Rong Shao , Gigi Feng , Jingwu Zang , Jielun Zhu , Drug Administration Law , Shenyang Pharmaceutical University , National Institute Of Diabetes , Prnewswire The Company Nasdaq , China Medical University , Fund Management Co , Chinese Journal Of Health , China Pharmaceutical University , China Society For Drug Regulation , China Pharmaceutical Association , Drug Administration , Research Center , Piacente Group Inc , Exchange Commission , Remegen Inc ,

Fierce Pharma Asia—Lilly-Innovent's PD-1 review; Takeda-Bayer patent settlement; Novo's Hummingbird investment

Eli Lilly and Innovent Biologics will face an FDA advisory committee for their PD-1 application in lung cancer. Takeda and Bayer put to rest their hemophilia patent infringement lawsuit. Novo Holdings led a $125 million series C in Singapore's Hummingbird Bioscience. And more. ....

United States , Innovent Biologics , Kinnate Biopharma , Daiichi Sankyo Enhertu , Landos Bioparma , Roche Tecentriq , Eli Lilly , Novo Holdings , Novo Nordisk , Hummingbird Bioscience , Orbimed Asia Partners , Daiichi Sankyo , Wuxi Biologics , Novo Nordisk , S Fda , I Mab , Wuxi Biologics , Wuxi Sta , Pd 1 L1 , Non Small Cell Lung Cancer , Patent Infringement , Patent Lawsuits , Sfda Inspection , Plant Inspections , Antibody Drug Conjugates , Inflammatory Bowel Disease ,

I-Mab Added to MSCI China Index

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization. ....

United States , Hong Kong , San Diego , Emilie Wu , Gigi Feng , Jielun Zhu , Exchange Commission , Prnewswire The Company Nasdaq , Piacente Group Inc , All Shares Index , Markets Index , Index Review , Chief Financial Officer , Chief Financial , Chief Communications , Piacente Group , I Mab , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , சான் டியாகோ , எமிலீ வு , பல் ஃபெங் , பரிமாற்றம் தரகு , பியசெந்தே குழு இன்க் , அனைத்தும் பங்குகள் குறியீட்டு , சந்தைகள் குறியீட்டு ,

I-Mab Announces Upcoming Participation at March Conferences

Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March. Details of the conferences and management presentation are as follows:
H.C. Wainwright Global Life Sciences Conference (Virtual)
Presentation: Tuesday, March 9, 2021 at 7:00 a.m. EST
Presenter: Mr. Jielun Zhu, Director and Chief Financial Officer
Webcast link: https://journey.ct.events/view/82bf84ac-4e9c-4ebd-baab-b0bf034e93af. The webcast will also be available under Event Calendar on IMAB s IR website at http://ir.i-mabbiopharma.com/. ....

United States , Hong Kong , San Diego , Emilie Wu , Morgan Stanley Hong Kong , Joan Huaqiong Shen , Gigi Feng , Leah Liu , Jingwu Zang , Jielun Zhu , Morgan Stanley , Company Nasdaq , Credit Suisse , Piacente Group Inc , Global Life Sciences Conference , Chief Financial , Honorary Chairman , Chief Executive Officer , Chief Financial Officer , Suisse Asian Investment Conference , Stanley Hong Kong Summit , Chief Communications , Piacente Group , I Mab , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் ,